Roche has dismissed recent reports that said the drugmaker was considering exiting the diabetes business.
Instead, Roche is looking to expand its $2 billion-per-year diabetes biz -- not sell it or spin it off, said Diagnostics division head Roland Diggelmann.
Rumors started after Bloomberg reported that Roche was open to a possible spin-off or a partial stake sale of its diabetes care unit, claiming that private equity players and medical device makers had expressed interest in acquiring the business.
Despite Roche's 5% decline in revenues for the unit, Roche says that it remains committed to diabetes care.
Read the Reuters coverage